Home Articles Research Summary Full Study
Full Study Text
Cognitive Enhancement of Healthy Older Adults Using Hyperbaric Oxygen: A Randomized Controlled Trial
Abstract
More than half of community-dwelling individuals sixty years and older express concern about declining cognitive abilities. The current study's aim was to evaluate hyperbaric oxygen therapy (HBOT) effect on cognitive functions in healthy aging adults.
A randomized controlled clinical trial randomized 63 healthy adults (>64) either to HBOT (n=33) or control arms (n=30) for three months. Primary endpoint included the general cognitive function measured post intervention/control. Cerebral blood flow (CBF) was evaluated by perfusion magnetic resonance imaging.
There was a significant group-by-time interaction in global cognitive function post-HBOT compared to control (p=0.0017). The most striking improvements were in attention (net effect size=0.745) and information processing speed (net effect size=0.788).
Voxel-based analysis showed significant cerebral blood flow increases in the HBOT group compared to the control group in the right superior medial frontal gyrus (BA10), right and left supplementary motor area (BA6), right middle frontal gyrus (BA6), left middle frontal gyrus (BA9), left superior frontal gyrus (BA8) and the right superior parietal gyrus (BA7).
In this study, HBOT was shown to induce cognitive enhancements in healthy aging adults via mechanisms involving regional changes in CBF. The main improvements include attention, information processing speed and executive functions, which normally decline with aging.
Introduction
More than half of community-dwelling individuals, sixty years and older, express concern about declining cognitive abilities. Besides common pathological declines such as in Alzheimer's dementia and mild cognitive impairments, normal cognitive aging is part of the normal aging process. Processing speed, conceptual reasoning, memory and problem-solving activities are the main domains which decline gradually over time.
Cerebrovascular dysfunction is an additional distinctive feature of aging that includes endothelial-dependent vasodilatation and regional decreases in cerebral blood flow (CBF). Although not associated with a specific pathology, reduced regional CBF is associated with impaired cognitive functions.
A growing body of research suggests several methods for cognitive enhancement and for improving the quality of life in both healthy and pathological states. Non pharmacological lifestyle interventions including exercise, healthy diets and cognitive training have shown positive effects if intensively performed. Unfortunately, so far, pharmacological interventions did not show significant improvements in cognitive performance in normal aging, and have significant risks for side effects.
Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen in an environmental pressure higher than one absolute atmospheres (ATA) to enhance the amount of oxygen dissolved in body's tissues. Repeated intermittent hyperoxic exposures has been shown to induce physiological effects which normally occur during hypoxia in a hyperoxic environment, including stem cells proliferation and generation of new blood vessels (angiogenesis). Angiogenesis is induced mainly in brain regions signaling ischemia or metabolic dysfunction. In turn, neovascularization can enhance cerebral blood flow and consequently improve the metabolic activity.
There is growing evidence from clinical studies that HBOT, utilized in a repeated daily sessions protocol, has neurotherapeutic effects which can improve cognitive functions in post-stroke, traumatic brain injury and anoxic brain damaged patients even years after the acute insult. However, no study to date has examined HBOT's neurocognitive effects in normal aging populations.
The aim of the current study was to evaluate whether HBOT affects cognitive function and brain perfusion in normal, non-pathological, aging adults.
Results
Out of 100 individuals that were contacted for participation, 70 were eligible and signed an informed consent. Seven patients did not complete baseline assessments and were excluded. All 63 patients who completed baseline evaluations completed interventions. One patient did not complete the cognitive assessment post-HBOT and was excluded from analysis. The HBOT arm patients were slightly older (70.7±3.6 compared to 68.8±3.3) and apart from a higher rate of atrial fibrillation in the HBOT arm (4 patients, 13.3% vs. no patients, 0%), there were no other significant differences between the two groups.
Cognitive function
Primary endpoint. Both groups had similar global cognitive scores at baseline, which was higher than the average score normalized to age and education level (>100). There was a significant group-by-time interaction in the primary endpoint of global cognitive function post-HBOT compared to the control group (F=10.811, p=0.0017, with a net effect size of 0.849).
Secondary endpoints. Both groups had similar cognitive scores in all domains measured by NeuroTrax at baseline. The most striking improvements were in attention (net effect size=0.745, F=8.445, p=0.005) and information processing speed (net effect size=0.788, F=9.142, p=0.003). Both overall memory domain score, the immediate and delayed nonverbal memory scores were all improved post-HBOT compared to the control group, though they were statistically insignificant following multi-comparisons corrections.
In the CANTAB battery, the HBOT group showed significant improvement in set-shifting task performance (a subset of executive function), with a significant reduction in median response time in both congruent (net effect size=−0.861, p=0.002) and incongruent trials (net effect size=−0.840, p=0.001) following HBOT. There was an increased performance in the visual memory task post-HBOT, which was statistically insignificant following multiple comparisons corrections.
In the traditional paper-and-pencil tasks, both verbal fluency (FAS semantic, net effect size=0.566, p=0.03) and verbal memory (RAVLT total, net effect size=0.603, p=0.02) improved in the HBOT group compared to the control group, though these did not remain significant after multiple-comparisons correction.
Brain perfusion
Ten subjects were excluded due to excessive head motion, and ten subjects were excluded due to low or wide arterial input function. A total of 20 subjects from the control group and 19 subjects from the HBOT group were included in the perfusion analysis.
There was an insignificant increase in whole-brain CBF (p=0.054) and whole grey-matter CBF (p=0.057), with no significant group-by-time interaction in whole-brain, grey-matter, or white-matter CBF.
Voxel-based analysis revealed significant CBF increases in the HBOT group compared to the control group in: right superior medial frontal gyrus (BA10), right and left supplementary motor area (BA6), right middle frontal gyrus (BA6), left middle frontal gyrus (BA9), left superior frontal gyrus (BA8), and right superior parietal gyrus (BA7).
There were moderate correlations between cognitive score changes and these regional perfusion changes. The memory score change correlated with left middle frontal gyrus CBF change (r=0.379, p=0.023), and the attention score change correlated with the right middle frontal gyrus (r=0.339, p=0.043). The RAVLT total score correlated with the right superior medial frontal gyrus (r=0.393, p=0.016), right supplementary motor area (r=0.394, p=0.016), and the right superior parietal gyrus (r=0.380, p=0.002).
Quality of life
At baseline, there were no significant differences in quality-of-life domains as calculated from the SF-36 questionnaire. There was a significant increase in the HBOT group's energy levels, compared to none in the control group.
Safety
Four participants (13.3%) experienced mild middle-ear barotrauma in the HBOT group compared to none in the control group; all events were treated conservatively and all participants completed their protocol. Fifteen participants (62% of those without intraocular lens implantation) had visual acuity changes in the HBOT group, compared to ten (37%) in the control group; no changes were found in participants with prior intraocular lens surgery. Four participants (16.7%) in the HBOT group, compared to nine (33.3%) in the control group, had cataract level acceleration.
| Total (N=63) | Control (N=33) | HBOT (N=30) | P-value | |
|---|---|---|---|---|
| Age (years) | 69.70±3.59 | 68.81±3.34 | 70.68±3.64 | 0.041 |
| Males | 39 (61.9%) | 23 (69.7%) | 16 (53.3%) | 0.182 |
| Education (years) | 15.23±2.81 | 15.03±2.87 | 15.45±2.78 | 0.564 |
| Hypertension | 14 (22%) | 7 (21.2%) | 7 (23.3%) | 0.84 |
| Diabetes mellitus | 10 (15.9%) | 7 (21.2%) | 3 (10%) | 0.308 |
| Domain | Control: Baseline → 3mo | HBOT: Baseline → Post-HBOT | HBOT P-value | Net Effect Size |
|---|---|---|---|---|
| Global cognitive score | 102.19→103.00 (p=0.054) | 105.37→110.58 | <0.000* | 0.849 |
| Memory | 105.20→105.53 (p=0.757) | 104.23→108.46 | 0.004* | 0.593 |
| Executive Function | 100.83→102.15 (p=0.207) | 109.17→113.0 | 0.008* | 0.381 |
| Attention | 99.96→101.10 (p=0.247) | 102.89→108.90 | <0.000* | 0.745 |
| Information Processing Speed | 104.42→104.02 (p=0.908) | 107.86→116.02 | <0.000* | 0.788 |
| Motor Skills | 100.29→99.90 (p=0.746) | 104.63→107.79 | 0.075 | 0.445 |
*Satisfied Bonferroni corrections for multiple comparisons. Full data for all measured domains, including the CANTAB and paper-and-pencil batteries, appear in Tables 2–3 of the original publication.
| Anatomical location | Brodmann Area | t-value |
|---|---|---|
| Right superior medial frontal gyrus | 6 | 4.63 |
| Right supplementary motor area | 6 | 3.72 |
| Left supplementary motor area | 6 | 3.92 |
| Right middle frontal gyrus | 6 | 4.56 / 3.8 |
| Left middle frontal gyrus | 9 / 8 | 4.52 / 4.13 |
| Right superior frontal gyrus | 10 | 4.04 |
| Right superior parietal gyrus | 7 | 4.41 / 4.21 |
Discussion
The study found HBOT can induce significant enhancements in cognitive performance in healthy elderly. The main improved domains include attention, information processing speed and executive function (set shifting) in addition to global cognitive functions. Moreover, the HBOT group had significantly enhanced brain perfusion in the superior and middle frontal gyri, supplementary motor area and superior parietal lobule.
Attention and information processing speed were significantly increased following HBOT compared to no change in the control group. In executive functions, the particular subset of set shifting improved significantly following HBOT compared to actual deterioration in the control group. These domains are known to gradually decline within the process of normal aging and play a crucial role in the daily functioning of the elderly. The results were obtained in participants who had neither previous brain pathologies nor pathological cognitive declines and had normal baseline cognitive scores.
The memory domain, and mainly the non-verbal subdomain, improved in the HBOT group compared to no change in the control group, though these changes did not reach corrected significance; the authors note larger sample sizes might allow this effect to remain significant after correction.
The net effect size of global cognitive score enhancement (0.849) following 12 weeks of HBOT sessions was found to be substantially larger than effect sizes reported for other enhancement modalities, including aerobic exercise training in prior meta-analyses.
The proposed mechanism draws on the "hyperoxic-hypoxic paradox": intermittent hyperoxic exposures induce many of the physiological responses that normally occur during hypoxia, including release of hypoxia-inducible factor (HIF), which in turn modulates release of vascular endothelial growth factor (VEGF), the master regulator of angiogenesis. As seen in ischemic brain injuries, this neovascularization can increase regional cerebral blood flow. The authors suggest repeated oxygen-level fluctuations may improve regional CBF and cognitive functions in healthy elderly through this mechanism.
The protocol used 60 sessions of 100% oxygen at 2 ATA, including three air breaks per session, specifically to utilize the hyperoxic-hypoxic paradox while minimizing oxygen toxicity risk.
Study limitations noted by the authors include: a limited sample size; a non-intervention (rather than sham-intervention) control group, meaning participants were not blinded even though outcome assessors were; and that the duration of the effect beyond the study period has not yet been determined in long-term follow-up. Strengths include isolation of the HBOT effect (both groups were monitored for lifestyle, medication, and other confounding changes), use of alternate cognitive-test forms with established test-retest validity, and correlation between cognitive improvements and objective perfusion-MRI changes.
Materials and Methods
Subjects. Seventy adults without pathological cognitive decline, aged 64 and older, living independently in good functional and cognitive status, were enrolled at Shamir (Assaf-Harofeh) Medical Center, Israel, between 2016–2020. Exclusion criteria included recent HBOT treatment, malignancy history, pathological cognitive decline, severe chronic renal failure, uncontrolled diabetes, immunosuppressant use, MRI contraindications, active smoking, and pulmonary disease.
Study design. A randomized, prospective controlled clinical trial approved by the Institutional Review Board of Shamir Medical Center. Subjects were assigned to HBOT or control (no intervention) arms; assessors were blinded to intervention assignment. Measurements were taken at baseline and 1–2 weeks after the HBOT or control period.
Intervention. The HBOT protocol was administered in a multiplace Starmed-2700 chamber (HAUX, Germany): 60 daily sessions, 5 sessions per week over three months. Each session involved breathing 100% oxygen by mask at 2 ATA for 90 minutes, with 5-minute air breaks every 20 minutes. Compression/decompression rates were 1 meter/minute. The control arm received no active intervention. Neither lifestyle/diet changes nor medication adjustments were permitted for either group during the trial.
Cognitive measures. Assessed using the NeuroTrax computerized battery (memory, executive function, attention, information processing speed, motor skills), the CANTAB computerized battery (attention switching, visual memory, reaction time, sustained attention, working memory), and a traditional paper-and-pencil neuropsychological battery (Rey-Osterrieth Complex Figure Test, Rey Auditory Verbal Learning Test, digit symbol substitution, digit span, five-point test, trail-making test, FAS verbal fluency, bells test), all normalized to age, gender, and education.
Brain MRI. Scans were performed on a MAGNETOM Skyra 3T scanner with dynamic susceptibility contrast (DSC) perfusion imaging and post-contrast high-resolution MPRAGE 3D T1-weighted images. Whole-brain quantitative perfusion analysis followed established methods, with cerebral blood flow (CBF) calculated on a voxel-by-voxel basis following arterial input function determination, gamma-variate fitting, and SVD deconvolution.
Statistical analysis. A within-subject repeated-measures ANOVA model tested the main interaction effect between time and group for both cognitive scores and CBF, with false discovery rate correction for multiple comparisons and covariate adjustment for age, sex, and education. Sample size was calculated to require 70 total participants (allowing for a 15% dropout rate) at 80% power and alpha of 5%.
Funding
The study was funded by a research grant from the Sagol Network for Neuroscience, established by Mr. Sami Sagol.
Conflicts of Interest
As disclosed in the original publication: A. Hadanny, S. Efrati, R. Boussi-Gross, G. Suzin, Y. Bechor, and Y. Zemel work for AVIV Scientific LTD; S. Efrati is a shareholder at AVIV Scientific LTD.
Let's Talk
You don't need a diagnosis in hand to reach out.
We're happy to walk through the science, the evidence, and what to expect. Tell us a little about your situation and we'll take it from there — no pressure, no obligation.